Literature DB >> 16452986

Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.

Caroline Louis1, Caroline Cohen, Ronan Depoortère, Guy Griebel.   

Abstract

The vasopressin 1b receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, are orally active non-peptidic compounds with anxiolytic- and antidepressant-like activities in animal models. Presently, SSR149415 and SSR125543 were evaluated in a differential reinforcement of low-rate 72 s (DRL-72 s) schedule, a procedure known to respond differentially to antidepressants and anxiolytics. Male Wistar rats were trained to lever-press for food reinforcement, but only lever-presses occurring after a 72 s delay were reinforced; otherwise, presses were not rewarded, and the timer was reset to 0 s. The selective serotonin reuptake inhibitor, fluoxetine, and the benzodiazepine anxiolytic, diazepam, were tested in parallel. SSR149415 (10-30 mg/kg, i.p.) and SSR125543 (30 mg/kg, i.p.) increased the percentage of responses emitted in the inter-response time (IRT) bin (49-96 s), which resulted in a greater number of reinforced presses. Both compounds shifted the frequency distribution of responses toward longer IRT durations, with a preservation of the bell shape of the IRT distribution curve. Fluoxetine (10 mg/kg, i.p.) had an effect on DRL-72 s similar to that of SSR149415 and SSR125543. By contrast, diazepam increased the number of responses in IRT bin (0-12 s), and the IRT distribution curve was shifted toward shorter IRT durations and flattened. In summary, these results show that SSR149415 and SSR125543 displayed antidepressant-like activity in a DRL-72 s schedule in rat, confirming their therapeutic potential for the treatment of pathological states induced by chronic frustration such as depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452986     DOI: 10.1038/sj.npp.1301036

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  12 in total

1.  Chronic treatment with the vasopressin 1b receptor antagonist SSR149415 prevents the dysphoria associated with nicotine withdrawal in rats.

Authors:  Xiaoli Qi; Lidia Guzhva; Yue Ji; Adriaan W Bruijnzeel
Journal:  Behav Brain Res       Date:  2015-06-22       Impact factor: 3.332

Review 2.  Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Authors:  John H Kehne; Christopher K Cain
Journal:  Pharmacol Ther       Date:  2010-09-06       Impact factor: 12.310

Review 3.  Open questions in current models of antidepressant action.

Authors:  A Tanti; C Belzung
Journal:  Br J Pharmacol       Date:  2010-02-02       Impact factor: 8.739

4.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Authors:  M E Breuer; M M van Gaalen; W Wernet; S E F Claessens; R S Oosting; B Behl; S M Korte; H Schoemaker; G Gross; B Olivier; L Groenink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-31       Impact factor: 3.000

Review 5.  Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?

Authors:  Catherine Belzung
Journal:  Neuropsychopharmacology       Date:  2013-12-18       Impact factor: 7.853

6.  Prenatal choline supplementation alters the timing, emotion, and memory performance (TEMP) of adult male and female rats as indexed by differential reinforcement of low-rate schedule behavior.

Authors:  Ruey-Kuang Cheng; Christopher J MacDonald; Christina L Williams; Warren H Meck
Journal:  Learn Mem       Date:  2008-03-05       Impact factor: 2.460

Review 7.  Depression and antidepressants: molecular and cellular aspects.

Authors:  Cristina Lanni; Stefano Govoni; Adele Lucchelli; Cinzia Boselli
Journal:  Cell Mol Life Sci       Date:  2009-06-12       Impact factor: 9.261

Review 8.  The vasopressin Avpr1b receptor: molecular and pharmacological studies.

Authors:  Ja Roper; A-M O'Carroll; Ws Young; Sj Lolait
Journal:  Stress       Date:  2010-09-09       Impact factor: 3.493

9.  Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study.

Authors:  Agorastos Agorastos; Anne Sommer; Alexandra Heinig; Klaus Wiedemann; Cüneyt Demiralay
Journal:  Front Psychiatry       Date:  2020-05-20       Impact factor: 4.157

Review 10.  Vasopressin V1B Receptor Antagonists as Potential Antidepressants.

Authors:  Shigeyuki Chaki
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.